Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | NK-CAR immunotherapy: the next steps

Evelyn Ullrich • 1 Sep 2020
EBMT 2020
General CAR-T NK-Cell Therapy

Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, discusses the next steps with respect to NK-CAR immunotherapy, highlighting a multicenter Phase II study and issues for future studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Evelyn Ullrich

The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies
2:06
The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies
Evelyn Ullrich • 11 Apr 2025
Advances in gene engineering technologies for NK cell-based immunotherapy
2:08
Advances in gene engineering technologies for NK cell-based immunotherapy
Evelyn Ullrich • 24 Apr 2023
Immunity of patients with multiple myeloma after vaccination against COVID-19
2:17
Immunity of patients with multiple myeloma after vaccination against COVID-19
Evelyn Ullrich • 5 Dec 2022
Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML
3:09
Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML
Evelyn Ullrich • 5 Dec 2022

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals